

# Modes of cancer cell invasion and the role of the microenvironment

Andrew G Clark<sup>1,2</sup> and Danijela Matic Vignjevic<sup>1,2</sup>



Metastasis begins with the invasion of tumor cells into the stroma and migration toward the blood stream. Human pathology studies suggest that tumor cells invade collectively as strands, cords and clusters of cells into the stroma, which is dramatically reorganized during cancer progression. Cancer cells in intravital mouse models and *in vitro* display many 'modes' of migration, from single isolated cells with round or elongated phenotypes to loosely-/non-adherent 'streams' of cells or collective migration of cell strands and sheets. The tumor microenvironment, and in particular stroma organization, influences the mode and dynamics of invasion. Future studies will clarify how the combination of stromal network structure, tumor cell signaling and extracellular signaling cues influence cancer cell migration and metastasis.

## Addresses

<sup>1</sup> Institut Curie, PSL Research University, 75005 Paris, France

<sup>2</sup> CNRS, UMR144, 75005 Paris, France

Corresponding author: Clark, Andrew G ([andrew.clark@curie.fr](mailto:andrew.clark@curie.fr))

Current Opinion in Cell Biology 2015, 36:13–22

This review comes from a themed issue on **Cell adhesion and migration**

Edited by **Michael Sixt** and **Erez Raz**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 14th July 2015

<http://dx.doi.org/10.1016/j.ceb.2015.06.004>

0955-0674/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Metastasis is a hallmark of cancer and the leading cause of mortality among cancer patients [1]. Cancer, in its most virulent form, is thus not only a disease of uncontrolled cell growth, but also a disease of uncontrolled cell migration. The first step in metastasis is the migration of cancer cells away from the primary tumor, a process called *tumor invasion* (Figure 1). In solid epithelial tumors, or *carcinomas*, invading cells must first cross the basement membrane (BM). The BM is a natural barrier between the epithelium and the *stroma*, a network of extracellular matrix (ECM) populated by a number of other cell types that surrounds the tissue. Metastasizing cells migrate through the stroma to reach blood or lymph vessels, where they can be carried to other organs. In this review, we will focus on the migration of cancer cells through the stroma. The mechanisms of BM invasion have recently been reviewed [2].

We will first discuss general features of cancer cell migration through the stroma, with a focus on tumor cell morphology and migration mode. Next, we will summarize findings specifically from human pathology studies, *in vivo* studies employing intravital imaging techniques, and *in vitro* systems, highlighting tumor–stroma interactions. Finally, we draw attention to the similarities and differences in findings using these different systems and discuss outstanding questions in the field.


## Modes of cancer cell migration

Both human pathology studies and intravital imaging studies in mouse systems have revealed a great diversity in the morphologies of invading cancer cells and the way these cells migrate. Cancer cells possess a unique ability to adapt to different environmental conditions, assuming different morphologies and migration characteristics in order to stay motile [3]. *In vivo*, motile tumor cells have been observed to migrate individually as single cells, as loosely-attached cell streams and as well-organized, adherent collectives. In human cancer pathology studies, cancer cells from epithelial tumors primarily invade collectively, while in intravital imaging studies, cancer cells display a wide range of different migration modes and morphologies (Box 1).

*In vitro* studies have identified several intrinsic factors regulating migration mode and morphology. In cancer cells migrating individually, increased contractility, under control of the Rho-pathway, favors amoeboid-like migration, while lower contractility (and/or increased adhesion) favors more mesenchymal phenotypes [4–7]. Increased cell-cell interactions *via* cadherins and cell-ECM binding *via* integrins can promote collective migration in cancer cells (reviewed in [3]). It is not currently well understood how cell morphology affects a cell's ability or tendency to migrate individually or collectively. However, cells with amoeboid-like morphologies tend to migrate individually or in streams, while epithelial cells migrate collectively. Cells with mesenchymal morphologies can most readily switch between single-cell, streaming and collective migration modes. For example, in hepatocyte growth factor-treated MDCK cells, which have a mesenchymal phenotype, upregulation of N-cadherin activity can promote a switch from individual to collective cell migration [8].

In addition to intrinsic factors, the microenvironment plays a significant role in determining cancer cell migration mode and morphology. In the remainder of the

Figure 1



**Summary of tumor progression and invasion.** In tumors of epithelial origin, or *carcinomas*, hypertrophic cell growth causes the epithelial layer to become many cell-layers thick. At more advanced stages, carcinoma cells often lose apical-basal polarity and apical cilia and may appear disorganized, due to reduction in cell-cell contacts and cytoskeletal reorganization (see also Figure 2a; [28]). At this 'carcinoma *in situ*' stage, the cancer cells are still encapsulated by the BM. Due to cross-talk between tumor cells and stromal cells, the stroma becomes reactive. Reactive stroma is characterized by an increased presence of immune cells and fibroblasts, which can help to deposit ECM and reorganize the stromal network (mostly made of collagen-I). Stromal network fibers are initially loosely organized and appear 'curly' and later increase in density and stiffness. At late stages, collagen bundles form 'tracks' perpendicular to the BM. In invasive tumors, cancer cells perforate the BM or migrate through regions of dysfunctional BM deposition, allowing the tumor cells to invade the stroma and migrate toward the blood stream (reviewed in [2]). Stromal cells can also enter the tumor, leading to a mixing of cell types and further disorganization of the tissue.

review, we will describe different migration modes that have been observed in human pathology studies, intravital imaging studies and *in vitro* experiments and focus on the role of the microenvironment in determining migration mode.

### The pathology of tumor invasion in humans

In human epithelial cancers such as colorectal and breast cancers, invasive cells are typically observed to migrate collectively [15,16,17<sup>\*\*</sup>]. Invasive carcinomas often display a disorganized glandular structure (Figure 2a). From these neoplastic glands, strands and cords of tumor cells project into the stroma at the *invasive front* (Figure 2b–f; [18–20]). Scattered clusters of ~5 cells (*tumor buds*) have also been observed (Figure 2b,c,f; [21,22]). This suggests that invading tumor cells *in vivo* typically preserve cell-cell contacts, leading to collective migration of groups of cancer cells.

Invading cells often display characteristic Epithelial to Mesenchymal Transition (EMT) markers, such as down-regulation of E-cadherin and upregulation of Vimentin, and lose some epithelial characteristics, such as apical-basal polarity [23]. Despite these changes, in human cancers, invading cells usually do not have a typically

spindle-shaped mesenchymal phenotype. This has fueled a debate over the role of EMT in human cancer progression [15,20]. However, in pathological examinations, it may be difficult to distinguish stromal cells from individual tumor cells with spindle-shaped phenotypes, potentially leading to the rarity of observed mesenchymal tumor cells in human cancers. A recent study using 3D reconstructions of serial tissue slices found that invading tumor cells invade almost exclusively in a collective manner. Cells in invading buds only rarely display changes in morphology to spindle-shaped (mesenchymal) or rounded phenotypes, while exhibiting some changes in EMT markers [17<sup>\*\*</sup>].

Recent studies have uncovered that clusters of circulating tumor cells (CTCs), also called tumor microemboli, are present in the circulation of patients with invasive melanoma, lung cancer and renal cell carcinoma [24–26]. It is possible that the presence of microemboli in the circulation is due to intravasation of small groups of collectively-migrating tumor cells. A recent study using a mouse breast cancer model suggests that tumor cell clusters in the circulation may indeed arise from the entry of groups of tumor cells into vessels, rather than aggregation of cancer cells following intravasation [27<sup>\*</sup>]. It is

**Box 1 Cancer cell migration modes and dynamics**

**Single-cell migration** is characterized by a lack of cell-cell interactions during migration and low correlation in the migration pattern between a cell and its neighbors. Cells that migrate singly can display different phenotypes. In **amoeboid-like** migration, cells have a round cell-body phenotype and can differ dramatically in their protrusive activity. Amoeboid-like motility comes in several variants: 1) cells that rapidly change their morphology, have short thin protrusions, are devoid of blebs and move with high velocities (0.4–5  $\mu\text{m}/\text{min}$ ); 2) much slower cells with a blebbing morphology and chaotic movements; 3) cells with short cellular protrusions associated with proteolytic activity moving with low velocities ( $\sim 0.1 \mu\text{m}/\text{min}$ ). Other singly-migrating cells have a **mesenchymal** phenotype, which is characterized by an elongated ('spindle-shaped') cell body and longer protrusions. While the protrusions of such cells advance relatively rapidly ( $\sim 0.4 \mu\text{m}/\text{min}$ , our unpublished data), in some cases, the cell rear stays immobile, resulting in relatively slow net translocation ( $\sim 0.2 \mu\text{m}/\text{min}$ ).

**Multicellular streaming** is characterized by loosely- or non-adherent cells that migrate along the same path. Cells in streams have typical speeds of 1–2  $\mu\text{m}/\text{min}$  and significantly longer and straighter paths compared to isolated migratory cells and can display amoeboid-like or mesenchymal phenotypes [3].

**Collective** migration is characterized by groups of cells that retain cell-cell adhesions for long periods of time and display a high correlation in directionality between neighboring cells during migration. Cells move either as narrow linear strands lead by one leader cell or as broad, irregularly shaped sheets, which are multiple cells in diameter and lead by several leader cells [3,9,10\*]. Collectively migrating cells can display mesenchymal or epithelial phenotypes, and the phenotypes may differ between 'leader' and 'follower' cells in some cases [11]. Collective migration is typically the slowest mode of cancer cell migration (0.01–0.05  $\mu\text{m}/\text{min}$ ), but faster collective migration (0.2–1  $\mu\text{m}/\text{min}$ ) has been observed during development *in vivo* (e.g., [12–14]).

not currently clear if migration mode influences later metastasis. However, the same study demonstrated that such tumor cell clusters can more efficiently colonize secondary organs [27\*].

Distant metastases typically recapitulate the epithelial/glandular morphology of the primary tumor, with epithelial-like phenotypes. This could suggest that metastases arise from tumor cells with preserved epithelial characteristics that migrate and colonize other organs as clusters. Alternatively, individually-invading cells that have undergone EMT could undergo a *Mesenchymal to Epithelial Transition* (MET), upon reaching a secondary organ [23,28,29]. Indeed, cells with mesenchymal phenotypes are enriched in CTC populations in some breast and colon cancer patients, and the presence of mesenchymal CTCs correlates with poor prognosis [30,31].

During tumor progression, the stroma, which surrounds the epithelial tissues, also undergoes profound changes. The stroma is comprised primarily of a collagen-I network. In normal stroma, collagen fibers typically appear 'curly' and anisotropic [32]. During early cancer progression, the amount of collagen in the stroma increases, and

collagen fibers appear straighter and are aligned parallel to the tumor border [33\*\*]. Similar patterns have been found using a murine breast cancer model [34]. In invasive tumors, collagen fibers become bundled and are oriented perpendicularly to the BM, providing 'tracks' for cancer cells to migrate away from the primary tumor (Figure 1). This particular organization of collagen is correlated with poor patient survival [33\*\*].

The reorganization of the stromal network is primarily mediated by stromal cells, most prominently fibroblasts. Cancer-associated fibroblasts (CAFs) reorganize the stroma by secreting ECM and enzymes that covalently cross-link collagen fibers and by physically pulling on the collagen network [32,35,36]. As a result, the stromal network becomes stiffer. In breast cancers, neoplastic tissue can be two- to ten-fold stiffer than normal tissue. This increase in tissue stiffness is thought to primarily reflect changes in the stroma [37–39], while tumor cells themselves appear to become softer [40]. Breast tumors are more likely to develop in regions of high tissue density [41], and tissue density itself is a predictive risk factor in the development of breast cancer [42–44]. The dramatic reorganization of the stroma in invasive cancers is likely to contribute to changes in the migratory properties of tumor cells that lead to later metastasis [32]. Although many details of stromal evolution during tumor progression are yet to be determined, an increase in network stiffness and reorganization into thicker bundles appears to correlate with an increased risk for metastasis.


**Intravital imaging of cancer cell invasion**

With the introduction of multiphoton-based intravital imaging about 15 years ago, it became possible to observe cancer cell behavior during tumor invasion *in vivo* [45,46]. In intravital cancer cell migration experiments, tumors are usually generated by subcutaneously or orthotopically xenografting cancer cells that express fluorescent proteins. Alternatively, cancer cell migration can be studied in genetically modified animals that develop tumors spontaneously. Fluorescently-labeled dextran can be intravenously injected to highlight the vasculature, and stromal collagen fibers can be visualized using second harmonic generation (SHG). However, it is not currently possible to visualize changes in the stromal network during tumor progression, due to the relatively slow timescale of this process and challenges in long-term imaging in intravital studies. New tissue preparation methods may allow for the observation of the co-evolution of stromal structure and tumor progression on longer timescales. For excellent reviews on current intravital imaging techniques, refer to [9,47,48].

While most studies agree that the vast majority of cancer cells *in vivo* are immobile over periods of several hours, a wide range of different migration modes and phenotypes have been described for motile cancer cells (Table 1, Figure 3). In general, grafted cells that display amoeboid-like morphology, such as A375 and B16F2 melanoma



Figure 2



**Tumor invasion in human epithelial cancers.** (a–c) Colon tissue section from colon cancer patient stained with a  $\beta$ -catenin antibody (brown). (a) Section highlighting the difference in epithelial organization between normal glandular tissue (N) and a tumorous gland (T) separated by stroma (S). (b) Colon cancer tissue section showing the edge of a tumorous gland (T), the invasive front (IF) and more distal stroma (S), which has not yet been invaded. (c) Examples of invasion phenotypes from colon cancer tissue sections showing invasive gland structure (left, arrow), small tumor buds that have separated from body of the tumor (left, arrowheads) and a cord of connected invasive cells (right). (d) Finger-like strands of invading cancer cells in a singlet ring-type colon carcinoma, with  $\beta$ -catenin staining (brown). Modified from [83]. (e) Tissue section from breast cancer patient showing a group of invasive cancer cells (C) surrounded by stroma (S). Cells are stained for the transcriptional regulator heat shock factor 1 (HSF1; brown) and smooth muscle actin (SMA; pink). Modified from [84]. (f) Tissue section from an oral squamous cell carcinoma displaying thin cords and strands of tumor cells as well as smaller tumor buds at the invasive front. Cells are stained for the nerve growth factor receptor p75<sup>NTR</sup> (brown) and counterstained with hematoxylin (blue). Right: high-magnification zoom of outlined region in left image. Red arrows indicate invasive cells expressing p75<sup>NTR</sup>. Modified from [85].

cells, tend to migrate as single cells or as streams. Cells with predominantly mesenchymal phenotypes, like MTLn3 or HT-1080, are more prone to switching between single-cell and collective migration modes. Intravital imaging has been essential to building an understanding of tumor cell invasion dynamics and how the native tumor environment can impact invasion and metastasis.

Intravital imaging studies suggest that the stromal collagen network can significantly impact the mode and direction of cancer cell migration. In breast cancer models, while areas with low collagen density contain mostly non-motile cells, motile cells can be found in the proximity of large collagen bundles [55<sup>\*</sup>]. In fast-migrating cancer cells, both with amoeboid-like and mesenchymal phenotypes, cells orient their protrusions parallel to collagen bundles, using the bundles as ‘highways’ for efficient, directional migration [9,59,64]. Loosely connected streams of migrating cells and collectively migrating cell strands also align parallel to collagen fibers [9,61]. It has recently been suggested that breast tumor cell behavior (slow-moving and high ECM degradation *vs.* fast-moving and invasive) is influenced by a combination of collagen structure, presence of macrophages and proximity to blood vessels [57].

The microenvironments of nearby tissues can also influence tumor cell migration. For example, melanoma cells

in the dermis tend to migrate as fast, directional and collective strands along linear tracks of muscle fibers and nerves. In contrast, cells migrating in fatty connective tissue migrate slowly as a broad, poorly organized multicellular group lead by several leader cells, from which single cells occasionally detach [10<sup>\*</sup>]. Similarly for fibrosarcoma cells implanted in the deep dermis, loosely organized fat tissue favors single-cell migration, while muscle fibers and lymph vessels promote collective migration of multicellular strands [61]. These studies suggest that more organized/aligned environments may promote more collective migration.

The presence of nearby blood vessels can also influence migration, though it is unclear if this is due to differences in organization of the stromal network or signaling. Cancer cells are typically more motile in the proximity of blood vessels; however, there is no correlation between the occurrence of single-cell migration *vs.* streaming and blood vessel density [54,58,65]. The presence of macrophages, which are usually found near blood vessels, positively correlates with cancer cell motility [62]. It is hypothesized that macrophages help cancer cells to invade the stroma and to intravasate into blood vessels [62,66,67].

In spontaneous murine colorectal tumors, distinct invasive regions have been identified. In one region, thick and

**Table 1****Migration modes and dynamics observed by intravital imaging.**


Cell type	Fraction of motile cells	Migration mode	Speed	Reference
A375M2 human melanoma		70% amoeboid-like (single-cell; with and without blebs)	0.5–10 $\mu\text{m}/\text{min}$	[6]
A375 human melanoma	1–5%	30% mesenchymal 55% amoeboid-like (single cell; without blebs) 10% amoeboid-like (single cell; with blebs) 35% mesenchymal	amoeboid-like: $\sim 3 \mu\text{m}/\text{min}$ mesenchymal: $\sim 1 \mu\text{m}/\text{min}$ 1–5 $\mu\text{m}/\text{min}$	[49,50]
B16F2 mouse melanoma	6.6% (0–22% per field of view)	56% single-cell (amoeboid-like) 44% multicellular streaming	0.4–6.7 $\mu\text{m}/\text{min}$ amoeboid: $\sim 1 \mu\text{m}/\text{min}$ streaming: $\sim 2 \mu\text{m}/\text{min}$	[51]
B16F2 mouse melanoma	Most immobile	Single-cell (amoeboid-like, without blebs)	0.2–5 $\mu\text{m}/\text{min}$	[52]
B16F10 mouse melanoma		Collective (strands 3–5 cell diameters)	$\sim 0.25 \mu\text{m}/\text{min}$	[10*]
MTLn3 rat breast cancer	1.6% mobile	Single-cell		[53]
MTLn3 rat breast cancer	10–20 cells per field	30% single-cell 70% multicellular streaming	Single-cell: $\sim 0.77 \mu\text{m}/\text{min}$ streaming: $\sim 2.1 \mu\text{m}/\text{min}$	[54]
MTLn3E rat breast cancer	1–5% (0–15% per field of view)	30% single-cell 55% multicellular streaming 15% collective	Single-cell: $\sim 2.5 \mu\text{m}/\text{min}$ streaming: $\sim 1 \mu\text{m}/\text{min}$	[55*,56]
MDA-MB-231 human breast cancer	15%	Single-cell (without blebs or with invasive protrusions) multicellular streaming	Single-cell (without blebs): 0.4–4.2 $\mu\text{m}/\text{min}$ single-cell (invasive protrusions): 0.03–0.25 $\mu\text{m}/\text{min}$	[57]
MDA-MB-231 human breast cancer	$\sim 5\%$ (93% of fields have $\geq 1$ motile cell)	44% single-cell 56% multicellular streaming	Single-cell: $\sim 0.7 \mu\text{m}/\text{min}$ streaming: $\sim 1.2 \mu\text{m}/\text{min}$	[58]
TN1 human breast cancer (from effusion)	$\sim 5\%$ (66% of fields have $\geq 1$ motile cell)	44% single-cell 56% multicellular streaming	Single: $\sim 0.6 \mu\text{m}/\text{min}$ streaming: $\sim 0.9 \mu\text{m}/\text{min}$	[58]
CT26 mouse colon carcinoma	Most immobile	Single-cell (mesenchymal)	0.2 $\mu\text{m}/\text{min}$	[59], Unpublished data
A431 human squamous cell carcinoma		Single-cell (overexpression of E-cadherin to switch to collective)		[60]
HT-1080 human fibrosarcoma	90%	14% single-cell 86% collective (sheets and strands)		[61]
Spontaneous mouse breast tumors (MMTV-PyMT)	80% (if close to macrophage)		$\sim 3.9 \mu\text{m}/\text{min}$ (in proximity to macrophages; sig. slower away from macrophages)	[62]
Spontaneous mouse intestine tumors (NICD; <i>Trp53</i> <sup>-/-</sup> ; Villin-Cre <sup>ERT2</sup> )		Multicellular streaming collective (sheets and strands) occasional single-cell		[63**], Unpublished data

straight collagen bundles containing stromal cells surround collectively migrating sheets and strings of cancer cells. In contrast, regions with poorly organized, shorter and curly collagen fibers contain isolated cancer cells [63\*\*]. This further supports the hypothesis that ECM alignment may promote collective migration. However, in these tumors, it is difficult to distinguish between the effects of the microenvironment and genetic/signaling differences, given the heterogeneity of these tumor cells. In the case of xenografted tumors, which are usually generated from established cell lines and thus genetically similar, the range of different migration modes appears to

be limited (see Box 1), indicating that these migration modes are also heavily influenced by genetics and signaling cues. For example, in murine breast cancer cells, TGF $\beta$  signaling can promote a transition from an immobile epithelial-like state to individual amoeboid-like migration [56]. Future work will be required to address how the combination of microenvironment structure, genetics and signaling cues influences tumor cell migration modes and dynamics.

Although intravital imaging accurately captures cancer cell invasion in the native environment, such studies

Figure 3



**Modes of cancer cell migration *in vivo*.** (a, a') Two different areas in spontaneously growing murine intestinal tumors showing cell clusters and independently migrating cells (a) and cells migrating collectively as strands and small clusters (a'). Green: tumor cells (nuclei). Pink: collagen (by SHG). Blue: stromal cells (membrane). Modified from [63\*\*]. (b) Amoeboid-like migration of MTLn3 rat breast cancer cells in the mouse mammary fat-pad. Green: cancer cells (myosin light chain). Red: collagen (SHG). Modified from [74]. (c, c') Mesenchymal migration of mouse colon cancer CT26 cells in the mouse dermis at successive time points. Green: cancer cells. Pink: collagen (SHG). Arrows and asterisks indicate the protrusion tips for two different cells. Courtesy of Sara Geraldo. (d) Streaming migration of MTLn3 cells in the mouse mammary gland. Red: cancer cells (photoconverted Dendra2). Green: cancer cells in the bulk of the tumor (non-photoconverted Dendra2). Modified from [54]. (e) Collective migration of B16F10 mouse melanoma cells in the mouse dermis. Green: blood vessels. Red: collagen (SHG). Blue: cancer cells (nuclei). Yellow: cancer cells (cytoplasm). Modified from [9].

remain primarily descriptive, owing to the difficulty in assaying and modifying properties of the tumor cells and microenvironment. Due to limited resolution, most intravital imaging setups cannot currently be used to study sub-cellular activity. In contrast, *in vitro* studies offer a more precise, controlled environment to test different aspects of cancer cell migration at high resolution.

### Tumor cell migration modes *in vitro*

A number of techniques have been developed to study cell migration in 3D, in environments that closely resemble the *in vivo* setting [68,69]. As the number of intravital imaging studies has grown, it is becoming more apparent that the timescale of single-cell migration in cancer cells, both *in vivo* and *in vitro*, is  $\sim \mu\text{m}/\text{min}$ , while collective migration modes are typically slower (see Box 1). Networks for 3D migration studies are typically comprised of ECM components like collagen-I or matrigel, a dense network of primarily collagen-IV and laminin [70]. Matrigel is more

similar in composition to the basement membrane than the stroma and may not faithfully recapitulate the stromal microenvironment [2,71]. The properties of collagen-I networks (*e.g.*, fiber thickness, pore size, mechanical properties) depend on the polymerization conditions and can therefore be experimentally controlled [72].

The properties of collagen networks can influence 3D cancer cell migration. Both migration velocity and the requirement for proteolysis have been shown to depend on pore size [72]. High network density and/or inhibition of network degradation can promote contractility-dependent amoeboid-like migration [4,73,74], though the ability of cancer cells to migrate without degradation may depend on matrix cross-linking [75]. ECM network properties can also affect collectivity during migration. In a recent study, high collagen density was shown to favor proteolytic-dependent collective migration in cultured fibrosarcoma and melanoma cells, which display



mesenchymal phenotypes [76<sup>•</sup>]. Cells from fragments of primary breast carcinomas (both human and the mouse model MMTV-PyMT) are more likely to undergo collective migration when embedded in collagen-I compared with matrigel, which may reflect the differences in structure and/or composition between collagen-I and matrigel [77]. In collectively invading MMTV-PyMT fragments in 3D, leader cells display a distinctly elongated, mesenchymal phenotype and remain in close contact with follower cells [78].

Increased complexity in *in vitro* microenvironments will help to further study the role of the stroma in cancer cell invasion. Proteomics-based studies focused on determining the *matrisome* of different tissues (e.g. [79,80]) will help to design more relevant *in vitro* systems. As the ECM likely differs significantly between different cancer types, *in vitro* systems should be adapted to recapitulate the native stromal environment. In their microenvironment, tumor cells also interact with other tumor and stromal cells. Experimental systems combining cancer cells and stromal cells will help to understand the importance of heterologous cell-cell interactions during invasion and metastasis.

## Conclusions and outlook

Pathology, intravital and *in vitro* studies point to a dynamic regulation of cell migration in tumor cells. However, it is unclear why human epithelial cancer cells predominantly migrate collectively, while most cells observed *in vivo* using intravital techniques and *in vitro* studies migrate as single cells. One potential explanation for this discrepancy is the difference in the stromal environment. In human cancers, the tumor and stroma evolve together over months and years. In most intravital imaging studies, where tumor cells are implanted, the stroma has not had sufficient time to progress, either in terms of structure or stromal cell population. In addition, many intravital imaging studies use Nude mice to allow for the growth of xenografted tumor tissue; the lack of a sufficient immune response could affect stromal network remodeling or the chemical signals in the tumor environment, which could bias migration mode and morphology. Alternatively, human and mouse stroma may differ significantly enough to change the pattern of cancer cell invasion. To account for some of these potential sources of bias, mouse models that form spontaneous tumors may be a good alternative to grafting cancer cells in mice. These models allow for the co-evolution of the tumor and stroma in non-immunodeficient mice, providing a more realistic microenvironment for cancer cell migration as well as a heterogeneous population of tumor cells that more closely reflects the disease state. New genome-editing techniques such as CRIPR/Cas9 will allow for more flexibility in labeling and genetically modifying tumor and stromal cells to test mechanisms of migration and metastasis in intravital studies.

Another challenge for the future of cancer cell migration research will be to more directly relate findings from intravital imaging studies to human cancer. Several studies have already related findings from intravital studies to human disease. For example, specific alignment of collagen fibers, termed tumor-associated collagen signature (TACS), has been identified as an independent prognostic factor for breast cancer patients [33<sup>••</sup>]. Similarly, cellular arrangements composed of a carcinoma cell, a macrophage, and an endothelial cell, termed tumor microenvironment of metastasis (TMEM), are suggested to serve as an independent indicator for metastasis development [81]. Higher density of TMEM correlates with a greater chance that a patient will develop distant metastasis. These and similar studies could allow for the development of treatments to prevent metastasis targeted toward the microenvironment rather than tumor cells themselves.

Cancer cell invasion is a flexible and multi-factorial process. How does the combination of stromal network structure, genetics and signaling cues determine how cancer cells migrate? How might migration mode influence cancer progression? Is collective migration a more efficient route to metastasis? Cells migrating collectively could have improved chemokine sensing through leader exchange or multicellular signal integration, as recently shown in 2D [82], allowing them to more efficiently reach the circulation by following chemical cues. Alternatively, collective migration could allow for a greater diversity in tumor cells seeding other organs. More migratory cancer cells could 'pull' cancer stem cells through the stroma and secondary organs, allowing the cancer stem cells to nest and proliferate at metastatic sites. Groups of cancer cells could also be more resistant to attack by the immune system or mechanical stress. Work toward addressing these questions will help not only to understand the basic cell biology of cell migration, but will also help to understand the escape mechanisms cancer cells use to metastasize to distant organs.

## Acknowledgements

We thank Y. Attie, J. Barbazán, A. Simon and R. Staneva for helpful comments on the manuscript. We acknowledge support from the European Research Council (ERC starting grant STARLIN, 311263 to D.M.V.), INSERM (to D.M.V.), and the European Molecular Biology Organization (EMBO; postdoctoral fellowship to A.G.C.).

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Hanahan D, Weinberg RA: **Hallmarks of cancer: the next generation.** *Cell* 2011, **144**:646-674.
2. Glentis A, Gurchenkov V, Vignjevic DM: **Assembly, heterogeneity, and breaching of the basement membranes.** *Cell Adhes Migr* 2014, **8**:236-245.

3. Friedl P, Alexander S: **Cancer invasion and the microenvironment: plasticity and reciprocity.** *Cell* 2011, **147**:992-1009.
  4. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker E-B, Friedl P: **Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis.** *J Cell Biol* 2003, **160**:267-277.
  5. Sahai E, Marshall CJ: **Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.** *Nat Cell Biol* 2003, **5**:711-719.
  6. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, Sahai E, Marshall CJ: **Rac activation and inactivation control plasticity of tumor cell movement.** *Cell* 2008, **135**:510-523.
  7. Bergert M, Chandradoss SD, Desai RA, Paluch E: **Cell mechanics control rapid transitions between blebs and lamellipodia during migration.** *Proc Natl Acad Sci U S A* 2012, **109**:14434-14439.
  8. Shih W, Yamada S: **N-cadherin-mediated cell-cell adhesion promotes cell migration in a three-dimensional matrix.** *J Cell Sci* 2012, **125**:3661-3670.
  9. Alexander S, Weigelin B, Winkler F, Friedl P: **Preclinical intravital microscopy of the tumour-stroma interface: invasion, metastasis, and therapy response.** *Curr Opin Cell Biol* 2013, **25**:659-671.
  10. Weigelin B, Bakker G-J, Friedl P: **Intravital third harmonic generation microscopy of collective melanoma cell invasion.** *Intravital* 2012, **1**:32-43.
- The authors use intravital imaging to demonstrate that melanoma cells at different tissue interfaces migrate with different dynamics and as single cells or collectively. This provides evidence that the microenvironment plays an essential role in determining migration mode.
11. Khalil AA, Friedl P: **Determinants of leader cells in collective cell migration.** *Integr Biol* 2010, **2**:568-574.
  12. Haas P, Gilmour D: **Chemokine signaling mediates self-organizing tissue migration in the zebrafish lateral line.** *Dev Cell* 2006, **10**:673-680.
  13. Prasad M, Montell DJ: **Cellular and molecular mechanisms of border cell migration analyzed using time-lapse live-cell imaging.** *Dev Cell* 2007, **12**:997-1005.
  14. Caussinus E, Colombelli J, Affolter M: **Tip-cell migration controls stalk-cell intercalation during drosophila tracheal tube elongation.** *Curr Biol* 2008, **18**:1727-1734.
  15. Christiansen JJ, Rajasekaran AK: **Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.** *Cancer Res* 2006, **66**:8319-8326.
  16. Friedl P, Gilmour D: **Collective cell migration in morphogenesis, regeneration and cancer.** *Nat Rev Mol Cell Biol* 2009, **10**:445-457.
  17. Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, Kayser G, Kohler I, Bausch D, Hoepfner J et al.: **Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface.** *J Pathol* 2014, **234**:410-422.
- Using 3D reconstructions of serial immunostained sections of tumor tissue slices, this study provides quantitative evidence that human epithelial cancers invade in a predominantly collective fashion. This study also points out potential artifacts of using 2D slices and suggests that changes and cell morphology and expression of some EMT markers occur only rarely in invading cells.
18. Wicki A, Lehenbre F, Wick N, Hantusch B, Kerjaschki D, Christofori G: **Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton.** *Cancer Cell* 2006, **9**:261-272.
  19. Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Lae M, Louvard D, Ben-Ze'ev A, Robine S: **Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer.** *Cancer Res* 2007, **67**:6844-6853.
  20. Tarin D: **The fallacy of epithelial mesenchymal transition in neoplasia.** *Cancer Res* 2005, **65**:5996-6001.
  21. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T: **Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment.** *Proc Natl Acad Sci U S A* 2001, **98**:10356-10361.
  22. Prall F: **Tumour budding in colorectal carcinoma.** *Histopathology* 2007, **50**:151-162.
  23. Thiery JP: **Epithelial-mesenchymal transitions in tumour progression.** *Nat Rev Cancer* 2002, **2**:442-454.
  24. Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K, van der Laak J, de Waal R, Mulders P, Oosterwijk E et al.: **Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma.** *J Pathol* 2009, **219**:287-293.
  25. Hou J-M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJC, Greystoke A, Zhou C, Morris K et al.: **Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.** *J Clin Oncol* 2012, **30**:525-532.
  26. Khoja L, Shenjere P, Hodgson C, Hodgetts J, Clack G, Hughes A, Lorigan P, Dive C: **Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma.** *Melanoma Res* 2014, **24**:40-46.
  27. Aceto N, Bardia A, Miyamoto David T, Donaldson Maria C, Wittner Ben S, Spencer Joel A, Yu M, Pely A, Engstrom A, Zhu H et al.: **Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.** *Cell* 2014, **158**:1110-1122.
- This study shows, using a mouse model, that clusters of CTCs enter the blood stream and are significantly more likely to cause metastasis than isolated CTCs. This provides some of the first evidence of a connection between tumor invasion and colonization at a secondary organ.
28. Weinberg RA: *The Biology of Cancer: Garland Science.* 2006.
  29. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T: **Migrating cancer stem cells – an integrated concept of malignant tumour progression.** *Nat Rev Cancer* 2005, **5**:744-749.
  30. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM et al.: **Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.** *Science* 2013, **339**:580-584.
  31. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S: **Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.** *Clin Cancer Res* 2015, **21**:899-906.
  32. Egeblad M, Rasch MG, Weaver VM: **Dynamic interplay between the collagen scaffold and tumor evolution.** *Curr Opin Cell Biol* 2010, **22**:697-706.
  33. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ: **Aligned collagen is a prognostic signature for survival in human breast carcinoma.** *Am J Pathol* 2011, **178**:1221-1232.
- This study relates tumor-associated collagen signatures (TACS)-3, characterized by bundled/aligned collagen, with poor patient prognosis in a cohort of breast cancer patients. This provides strong evidence that changes in the stromal network affect later metastasis.
34. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ: **Collagen reorganization at the tumor-stromal interface facilitates local invasion.** *BMC Med* 2006, **4**:38.
  35. Kalluri R, Zeisberg M: **Fibroblasts in cancer.** *Nat Rev Cancer* 2006, **6**:392-401.
  36. Cox TR, Bird D, Baker A-M, Barker HE, Ho MWY, Lang G, Erler JT: **LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis.** *Cancer Res* 2013, **73**:1721-1732.
  37. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W et al.: **Matrix crosslinking forces tumor progression by enhancing integrin signaling.** *Cell* 2009, **139**:891-906.



38. Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, Eliceiri KW, Keely PJ, Seewaldt VL, Weaver VM: **Tumor mechanics and metabolic dysfunction.** *Free Radic Biol Med* 2015, **79C**:269-280.
  39. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH: **Mammographic density is related to stroma and stromal proteoglycan expression.** *Breast Cancer Res* 2003, **5**:R129-R135.
  40. Plodinec M, Loparic M, Monnier CA, Obermann EC, Zanetti-Dallenbach R, Oertle P, Hyotyla JT, Aebi U, Bentires-Alj M, Lim RY et al.: **The nanomechanical signature of breast cancer.** *Nat Nanotechnol* 2012, **7**:757-765.
  41. Ursin GaH-L, Linda, Parisky, Yuri R, Pike, Malcolm C, Wu, Anna H: **Greatly increased occurrence of breast cancers in areas of mammographically dense tissue.** *Breast Cancer Res* 2005, **7**:R605-R608.
  42. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R: **Mammographic features and breast cancer risk: effects with time, age, and menopause status.** *J Natl Cancer Inst* 1995, **87**:1622-1629.
  43. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ: **Mammographic densities and breast cancer risk.** *Cancer Epidemiol Biomarkers Prev* 1998, **7**:1133-1144.
  44. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MRE, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ et al.: **Heritability of mammographic density, a risk factor for breast cancer.** *N Engl J Med* 2002, **347**:886-894.
  45. Ahmed F, Wyckoff J, Lin EY, Wang W, Wang Y, Hennighausen L, Miyazaki J-i, Jones J, Pollard JW, Condeelis JS et al.: **GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice.** *Cancer Res* 2002, **62**:7166-7169.
  46. Wang W, Wyckoff JB, Frohlich VC, Oleynikov Y, Hüttelmaier S, Zavadil J, Cermak L, Bottlinger EP, Singer RH, White JG et al.: **Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling.** *Cancer Res* 2002, **62**:6278-6288.
  47. Riitsma L, Steller EJ, Ellenbroek SI, Kranenburg O, Borel Rinkes IH, van Rheeën J: **Surgical implantation of an abdominal imaging window for intravital microscopy.** *Nat Protoc* 2013, **8**:583-594.
  48. Ellenbroek SIJ, van Rheeën J: **Imaging hallmarks of cancer in living mice.** *Nat Rev Cancer* 2014, **14**:406-418.
  49. Pinner S, Sahai E: **Imaging amoeboid cancer cell motility in vivo.** *J Microsc* 2008, **231**:441-445.
  50. Pinner S, Sahai E: **PKD1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE.** *Nat Cell Biol* 2008, **10**:127-137.
  51. Manning CS, Hooper S, Sahai EA: **Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells.** *Oncogene* 2014, **0**:1-13.
  52. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, Bonvin E, Goding C, Sahai E: **Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.** *Cancer Res* 2009, **69**:7969-7977.
  53. Philippart U, Roussos ET, Oser M, Yamaguchi H, Kim H-D, Giampieri S, Wang Y, Goswami S, Wyckoff JB, Lauffenburger DA et al.: **A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis.** *Dev Cell* 2008, **15**:813-828.
  54. Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y, Pozzuto M, Stobezki R, Goswami S, Segall JE et al.: **Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer.** *J Cell Sci* 2011, **124**:2120-2131.
  55. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E: **Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility.** *Nat Cell Biol* 2009, **11**:1287-1296.
- In this study, the authors use intravital imaging to demonstrate that TGFβ can induce a switch between collective and single-cell migration in a murine breast cancer model. This provides evidence for the role of signaling cues in determining migration mode.
56. Giampieri S, Pinner S, Sahai E: **Intravital imaging illuminates transforming growth factor β signaling switches during metastasis.** *Cancer Res* 2010, **70**:3435-3439.
  57. Gligorijevic B, Bergman A, Condeelis J: **Multiparametric classification links tumor microenvironments with tumor cell phenotype.** *PLoS Biol* 2014, **12**:e1001995.
  58. Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, Condeelis JS: **Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors.** *Intravital* 2013, **2**:e25294.
  59. Geraldo S, Simon A, Elkhatib N, Louvard D, Fetter L, Vignjevic DM: **Do cancer cells have distinct adhesions in 3D collagen matrices and in vivo?** *Eur J Cell Biol* 2012, **91**:930-937.
  60. Canel M, Serrels A, Miller D, Timpson P, Serrels B, Frame MC, Brunton VG: **Quantitative In vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics.** *Cancer Res* 2010, **70**:9413-9422.
  61. Alexander S, Koehl GE, Hirschberg M, Geissler EK, Friedl P: **Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model.** *Histochem Cell Biol* 2008, **130**:1147-1154.
  62. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J: **Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.** *Cancer Res* 2007, **67**:2649-2656.
  63. Chanrion M, Kuperstein I, Barriere C, El Marjou F, Cohen D, Vignjevic D, Stimmer L, Paul-Gilloteaux P, Bieche I, Tavares Sdos R et al.: **Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut.** *Nat Commun* 2014, **5**:5005.
- Using spontaneously developed tumors, the authors observe isolated cancer cells, supporting the hypothesis that EMT may occur for cancer cells in vivo. This study also correlates the single-cell vs. collective migration with the organization of the stromal collagen network.
64. Sidani M, Wyckoff J, Xue C, Segall JE, Condeelis J: **Probing the microenvironment of mammary tumors using multiphoton microscopy.** *J Mammary Gland Biol Neoplasia* 2006, **11**:151-163.
  65. Kedrin D, Gligorijevic B, Wyckoff J, Verkhusha VV, Condeelis J, Segall JE, van Rheeën J: **Intravital imaging of metastatic behavior through a mammary imaging window.** *Nat Methods* 2008, **5**:1019-1021.
  66. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J: **A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.** *Cancer Res* 2004, **64**:7022-7029.
  67. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, Stanley ER, Segall JE, Condeelis JS: **Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop.** *Cancer Res* 2005, **65**:5278-5283.
  68. Shamir ER, Ewald AJ: **Three-dimensional organotypic culture: experimental models of mammalian biology and disease.** *Nat Rev Mol Cell Biol* 2014, **15**:647-664.
  69. Herrmann D, Conway JRW, Vennin C, Magenau A, Hughes WE, Morton JP, Timpson P: **Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment.** *Carcinogenesis* 2014, **35**:1671-1679.
  70. Kleinman HK, Martin GR: **Matrigel: basement membrane matrix with biological activity.** *Semin Cancer Biol* 2005, **15**:378-386.
  71. Rowe RG, Weiss SJ: **Breaching the basement membrane: who, when and how?** *Trends Cell Biol* 2008, **18**:560-574.
  72. Wolf K, te Lindert M, Krause M, Alexander S, te Riet J, Willis AL, Hoffman RM, Figdor CG, Weiss SJ, Friedl P: **Physical limits of cell migration: control by ECM space and nuclear deformation and**

- tuning by proteolysis and traction force. *J Cell Biol* 2013, **201**:1069-1084.
73. Friedl P, Wolf K: **Tumour-cell invasion and migration: diversity and escape mechanisms.** *Nat Rev Cancer* 2003, **3**:362-374.
  74. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E: **ROCK- and Myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo.** *Curr Biol* 2006, **16**:1515-1523.
  75. Sabeh F, Shimizu-Hirota R, Weiss SJ: **Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited.** *J Cell Biol* 2009, **185**:11-19.
  76. Haeger A, Krause M, Wolf K, Friedl P: **Cell jamming: collective invasion of mesenchymal tumor cells imposed by tissue confinement.** *Biochim Biophys Acta* 2014, **1840**:2386-2395.
- In this study, the authors embed spheroids of melanoma and breast cancer cells in collagen networks in vitro and demonstrate that high collagen density can induce a switch from single-cell to collective migration.
77. Nguyen-Ngoc K-V, Cheung KJ, Brenot A, Shamir ER, Gray RS, Hines WC, Yaswen P, Werb Z, Ewald AJ: **ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium.** *Proc Natl Acad Sci U S A* 2012, **109**:E2595-E2604.
  78. Cheung Kevin J, Gabrielson E, Werb Z, Ewald Andrew J: **Collective invasion in breast cancer requires a conserved basal epithelial program.** *Cell* 2013, **155**:1639-1651.
  79. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO: **The Matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices.** *Mol Cell Proteomics* 2012, **11** M111.014647.
  80. Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO: **Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.** *eLife* 2014, **3**:e01308.
  81. Robinson BD, Sica GL, Liu Y-F, Rohan TE, Gertler FB, Condeelis JS, Jones JG: **Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.** *Clin Cancer Res* 2009, **15**:2433-2441.
  82. Malet-Engra G, Yu W, Oldani A, Rey-Barroso J, Gov Nir S, Scita G, Dupré L: **Collective cell motility promotes chemotactic prowess and resistance to chemorepulsion.** *Curr Biol* 2015, **25**:242-250.
  83. Kartenbeck J, Haselmann U, Gassler N: **Synthesis of junctional proteins in metastasizing colon cancer cells.** *Eur J Cell Biol* 2005, **84**:417-430.
  84. Scherz-Shouval R, Santagata S, Mendillo Marc L, Sholl Lynette M, Ben-Aharon I, Beck Andrew H, Dias-Santagata D, Koeva M, Stemmer Salomon M, Whitesell L *et al.*: **The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy.** *Cell* 2014, **158**:564-578.
  85. Sølund TM, Brusevold IJ, Koppang HS, Schenck K, Bryne M: **Nerve growth factor receptor (p75NTR) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma.** *Histopathology* 2008, **53**:62-72.